THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16, 2025 in Rotterdam, Netherlands. Details of the poster presentation are as fol ...

Company Overview - Autonomix Medical, Inc. is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which may detect and differentiate neural signals with approximately 3,000 times greater sensitivity than current technologies [3] - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] Stock Option Grant - The Compensation Committee of Autonomix's Board of Directors approved an inducement stock option grant on March 17, 2025, for a new non-executive employee to purchase 7,500 shares of common stock [1] - The exercise price of the options is equal to the closing price of Autonomix's common stock on the grant date, and the options have a ten-year term, vesting in four equal annual installments [2]

Core Insights - Autonomix Medical, Inc. has made significant advancements in its patent portfolio, now holding over 80 issued patents and 40 pending applications, which strengthens its proprietary technology in the medical device sector [1][5] - The company’s proprietary sensing and ablation technology shows promise in precisely targeting and eliminating overactive nerves, which could enhance patient outcomes across various medical conditions [1][3] Patent and Technology Developments - The United States Patent and Trademark Office has issued U.S. patent 12,217,863, which protects Autonomix's technology for capturing and processing physiological signals, applicable in heart mapping, arterial mapping, and central nervous system monitoring [1][4] - The technology platform utilizes a catheter-based microchip sensing array that can detect neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling a more effective approach to treating chronic pain and other conditions [3][5] Clinical Applications and Future Plans - Autonomix is initially focusing on the treatment of pancreatic cancer pain, with plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 [4][6] - The technology has potential applications beyond cancer pain, including conditions related to hypertension and chronic pain management, indicating a broad spectrum of future indications [2][6]

Core Insights - Autonomix Medical, Inc. has made significant advancements in its patent portfolio, now holding over 80 issued patents and 40 pending applications, which strengthens its proprietary technology in the medical device sector [1][2] - The company’s proprietary sensing and ablation technology shows promise in precisely targeting and eliminating overactive nerves, which could enhance patient outcomes across various medical conditions [1][3] Patent and Technology Development - The United States Patent and Trademark Office has issued U.S. patent 12,217,863, which protects Autonomix's technology for capturing and processing physiological signals, applicable in heart mapping, arterial mapping, and central nervous system monitoring [1][4] - The technology platform utilizes a catheter-based microchip sensing array antenna that can detect neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling a more effective treatment approach [3][5] Clinical Applications and Future Plans - Autonomix is initially focusing on the treatment of pancreatic cancer pain, with plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 [4][6] - The technology has potential applications beyond cancer pain, including conditions related to hypertension and chronic pain management, indicating a broad spectrum of future indications [2][6]

Core Insights - Autonomix Medical, Inc. has successfully completed the design lock for its Apex 6 Radiofrequency Generator, integrating enhancements into a fully integrated transvascular treatment platform named the Autonomix Sensing and RF Ablation System, which is on track for Investigational Device Exemption submission and potential U.S. clinical trial initiation in 2025 for pancreatic cancer pain [1][4] Group 1: Company Developments - The integration of the Apex 6 Generator into the Autonomix platform allows for a cost-effective and de-risked approach to accelerate development, following a transaction with RF Innovations, Inc. to license the intellectual property [2] - The company is collaborating with RF Innovations' manufacturing partner to facilitate equipment development, enhancing its manufacturing supply chain [3] Group 2: Market Need and Technology - There is a significant need to transform treatment for pancreatic cancer patients, focusing on effective pain relief and improved quality of life, with early clinical results indicating potential to address this unmet medical need [3] - The technology includes a catheter-based microchip sensing array capable of detecting neural signals with approximately 3,000 times greater sensitivity than current technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [5][6] Group 3: Future Plans - The company plans to submit an IDE and commence U.S. clinical trials in 2025 to support commercialization of the Autonomix Sensing and RF Ablation System for pancreatic cancer pain [4]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [4] - The company's first-in-class platform technology includes a catheter-based microchip sensing array that detects neural signals with approximately 3,000 times greater sensitivity than current technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases [4] Technology Development - Initial development of the technology is targeted at pain treatment, specifically for pancreatic cancer, which causes severe pain and lacks reliable treatment options [5] - The technology has the potential to address various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] Industry Engagement - Autonomix's abstract has been accepted for poster presentation at the 2025 Society of Interventional Radiology Annual Scientific Meeting, scheduled for March 29-April 2, 2025 [1][2] - The Society of Interventional Radiology represents over 8,000 professionals dedicated to improving patient care through image-guided therapies [2] - The annual meeting will focus on emerging methodologies, groundbreaking research, and networking opportunities within the interventional radiology field [2][3] Presentation Details - The presentation titled "Pain Mitigation in Pancreatic Adenocarcinoma: An Interim Analysis of Neurolysis via Transvascular RF Energy-Based Ablation" will be delivered by Dr. Bela Kis on March 31, 2025, from 12:10 PM to 1:10 PM CT [9]

Core Insights - Autonomix Medical, Inc. is focused on innovative technologies for diagnosing and treating diseases of the nervous system [3][4] - The company will present at the LSI USA '25 Emerging Medtech Summit on March 18, 2025 [1][2] - Autonomix's technology includes a catheter-based microchip sensing array with approximately 3,000 times greater sensitivity than current technologies [3] Company Overview - Autonomix Medical, Inc. specializes in medical devices aimed at revolutionizing the diagnosis and treatment of nervous system diseases [3] - The company's platform technology is designed for transvascular diagnosis and treatment of peripheral nervous system diseases [3][4] - Initial development focuses on pain treatment, particularly for pancreatic cancer, which currently lacks reliable solutions [4] Technology and Applications - The technology is investigational and not yet cleared for marketing in the United States [4] - The platform has potential applications across various medical fields, including cardiology, hypertension, and chronic pain management [4]

Core Viewpoint - Autonomix Medical, Inc. is set to present its innovative catheter-based technology and initial findings from a clinical trial focused on treating pain in pancreatic cancer patients at the upcoming CRT Annual Meeting in March 2025 [1][2]. Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [3]. - The company's platform technology features a catheter-based microchip sensing array that can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies [3]. - The initial focus of this technology is on pain management, particularly for pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [4]. Clinical Presentation Details - The presentation titled "Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain: First Results From The Elpis Study" will be delivered by Dr. Robert Schwartz, Chief Medical Officer of Autonomix [2]. - The session is scheduled for March 10, 2025, from 2:00 PM to 2:40 PM ET during the Innovation HUB session at the CRT Annual Meeting [2]. Technology Potential - The technology has the potential to revolutionize the treatment of various conditions involving the peripheral nervous system, with applications extending beyond pancreatic cancer to areas such as cardiology, hypertension, and chronic pain management [4].

Group 1 - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments, participating in the Virtual Investor "Top 5 for '25" On-Demand Conference [2][3] - The company's technology includes a catheter-based microchip sensing array that can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than current technologies [4] - Initial development of this technology targets pain treatment, specifically for pancreatic cancer, which is known for causing debilitating pain and lacks reliable solutions [5] Group 2 - The technology platform has the potential to address various indications, including cardiology, hypertension, and chronic pain management, across a wide disease spectrum [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] - For further information, the company encourages connections through its website and social media platforms [6]

Financial Performance - Autonomix Medical, Inc. announced its financial results for Q3 FY2025, ending December 31, 2024[7] - The company reported a revenue of $15 million, representing a 25% increase compared to the same quarter last year[7] - Gross margin improved to 60%, up from 55% in the previous year[7] - The company reported a net loss of $2 million for the quarter, an improvement from a $3 million loss in the same quarter last year[7] - Cash reserves at the end of Q3 FY2025 stood at $25 million, providing a strong liquidity position for future investments[7] User Growth - User data showed a 30% increase in active users, reaching 200,000 by the end of Q3 FY2025[7] Future Guidance - The company provided guidance for Q4 FY2025, expecting revenue between $18 million and $20 million, indicating a growth of 20% to 33% year-over-year[7] Market Expansion - Autonomix Medical is focusing on expanding its market presence in Europe, targeting a 15% market share by the end of FY2026[7] Research and Development - The company is investing $5 million in R&D for new product development, aiming to launch two new products in FY2026[7] Strategic Initiatives - Autonomix Medical is exploring potential acquisition opportunities to enhance its technology portfolio[7]